Trial Profile
A Phase 1 trial evaluating pharmacokinetics, safety and tolerability of MIN-102 after administration of single and multiple ascending doses in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Oct 2020
Price :
$35
*
At a glance
- Drugs Leriglitazone (Primary)
- Indications Adrenoleucodystrophy; CNS disorders; Friedreich's ataxia
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- 16 Sep 2020 Results assessing translational approach to determine target concentrations of leriglitazone to support a Phase II study in Friedreich's ataxia, presented at the 24th International Congress of Parkinson's Disease and Movement Disorders.
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology
- 21 Mar 2017 Results presented in Minoryx Therapeutics media release.